Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Liposarcoma × Pioglitazone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Polycystic Ovary Syndrome 8 Insulin Resistance 7 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Diabetes Mellitus, Type 2 4 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Urinary Bladder Neoplasms 2 Metabolic Syndrome 2 Leukoplakia, Oral 2 Leukemia, Myeloid, Chronic-Phase 2 Inflammation 2 Diabetes Mellitus 2 Carotid Intimal Medial Thickness 1 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Sleep Apnea, Obstructive 1 Skin Neoplasms 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Pharmacokinetics of MDV3100 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Meningioma 1 Memory Disorders 1 Lung Neoplasms 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Leukemia, Myeloid, Acute 1 Hypogonadism 1 Hyperinsulinism 1

Interventions

Doxorubicin 20 Trabectedin 10 Radiotherapy 10 Ifosfamide 10 pazopanib 5 Gemcitabine 5 ribociclib 4 Specimen Handling 4 Docetaxel 4 Biopsy 4 selinexor 3 pembrolizumab 3 palbociclib 3 eribulin 3 X-Rays 3 Filgrastim 3 Cyclophosphamide 3 temsirolimus 2 pegfilgrastim 2 liposomal doxorubicin 2 cixutumumab 2 brostallicin 2 brigimadlin 2 belinostat 2 avelumab 2 abemaciclib 2 Vincristine 2 Temozolomide 2 Surgical Procedures, Operative 2 Sunitinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04794127 2026-02-18

TRABEPIO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

Liposarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡